Receptor binding profile of tibalosine, a new antihypertensive.

The ability of 1-(2,3-dihydro-5-benzo[b]thienyl]-2-(4-phenylbutylamino)-1- propanol-(erythro) (tibalosine, CP 804 S), a new antihypertensive agent, to interact with 11 different receptors has been studied by binding assays. Tibalosine interacts specifically with alpha- and beta-adrenergic receptors and calcium channel binding sites. Ki values (nmol/l) for inhibition of specific binding are 26, 1000, 1000 and 770 respectively for the alpha 1-adrenergic, beta 1- and beta 2-adrenergic receptors and calcium channel binding sites. The interaction with adrenergic receptors is stereoselective since CP 804 S/T, the threo derivative of tibalosine, exhibits Ki values 8 to 10 times higher than those of tibalosine. The selectivity ratio between alpha 1- and alpha 2-adrenergic receptors is about 400. Tibalosine and CP 804 S/T interact with the low affinity binding sites labelled by 3H-WB 4101 in rat brain membranes. These binding sites for putative Ca2+ channel inhibitors are present in rat heart membranes and have the same characteristics as those in rat brain membranes. These results are discussed in relation with the mechanism of tibalosine antihypertensive effect.

Characterization of solubilized serotonin (S2) receptors in rat brain.

[3H]Spiperone binding sites were solubilized from rat frontal cortex and striatum by means of the mild detergent, lysolecithin. In the frontal cortex, the binding sites were extracted from a microsomal membrane fraction which was found to be enriched in serotonin (S2) receptors when labeled either with [3H]spiperone or with [3H]lysergic acid diethylamide. Although the extraction yield was relatively low, the [3H]spiperone binding sites solubilized from the frontal cortex retained the high-affinity characteristics of serotonin (S2) receptors in the original membrane: low KD (1.4 nM); binding saturable, reversible, and stereospecific; and displaying a high affinity toward the most potent serotonin antagonists (pirenperone, pipamperone, ketanserin, methysergide, and mianserin). There was a very good correlation between the drug potencies in both soluble and membrane preparations. The molecular dispersion of the soluble extract was assessed by several criteria, including a low sedimentation coefficient in sucrose gradient. No specific binding sites could be extracted from the cerebellum. In contrast, few binding sites endowed with the characteristics of serotonin (S2) receptors were detected in lysolecithin extracts from rat striatum. However, the S2 sites became more apparent when a tetralin derivative was added to the incubation medium in order to prevent [3H]spiperone binding on solubilized dopamine receptors. In contrast, when microsomal membranes from rat striatum were treated with digitonin, the solubilized [3H]spiperone binding sites were only of a dopaminergic nature.

Potential affinity labels for the opiate receptor based on fentanyl and related compounds.

Derivatives of fentanyl, 3-methylfentanyl, sufentanil, and lofentanil, possessing chemo- or photoaffinity functionalities, were synthesized as potential affinity reagents for the opiate receptor. Opiate receptor binding constants (IC50) were determined in competition experiments with [3H]naloxone and [3H]naltrexone. Affinity-labeling experiments were generally unsuccessful, although some irreversible attachment was achieved with alpha-diazoamide 17 and aryl azide 23.